This is a review article and comprehensively summarized the current knowledge of PD-1/PD-L1 targeting therapy in hematological malignancies. Overall, this is informative and useful for the researchers and clinicians in the field relating to the hematological malignancy. However, there is a couple of concerns shown below for the manuscript.

1. The most important point which reduces our enthusiasm for this manuscript is on abbreviation. Because there are many unspecified abbreviations throughout the manuscript, it is hard to read it. This reviewer had to spend long time to read the manuscript. This is unkind for the readers. The authors should re-check all abbreviations throughout the manuscript and specify them at the first place where they appear. The authors are also recommended to make the list of abbreviations in alphabetical order and attach it as a supplement.

2. If there is a figure that explains structural features for PD-1 and PD-Ls, it is very helpful.

3. Line 16 and Line73, does immune point inhibitors mean immune checkpoint inhibitors?

4. Title of the Tables must be more specified.